New Plant-based Block Minimizes Background Signal for Immunohistochemistry and Immunofluorescence

BURLINGAME, Calif.
Sep 4, 2016

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces a ready-to-use (RTU) animal-free blocking agent and diluent for cell- and tissue-based immunohistochemistry (IHC) and immunofluorescence. This new plant-based block is an alternative to widely used animal-based blocks such as sera, BSA, casein and non-fat dry milk, enabling the lab to reduce the use of animal-derived reagents.

The RTU animal-free block can be used with both peroxidase and alkaline phosphatase antibody conjugates and all secondary detection reagents including polymer systems and avidin/biotin reagents that incorporate these enzymes. Because the new reagent eliminates the possibility of species cross-reactivity, the blocker can be used in multiple labeling IHC applications. The new block was designed using optimal conditions and neutral pH specificity.

“This new animal-free block was developed in response to customer demand,” explains Craig Pow, Ph.D., director of technical services for Vector Laboratories. “The ready-to-use aspect of the product is especially important, as investigators continuously look for ways to streamline workflows.”

About Vector Laboratories

Vector Laboratories develops, manufactures and markets labeling and detection reagents for immunohistochemistry, immunofluorescence, DNA/RNA and glycobiology. The company serves customers in disease and therapeutics research with tools that help them precisely visualize and study tissues and cells. A pioneer in a number of innovative technologies, Vector Laboratories has been providing a continuous stream of reliable tools to its customers for more than 40 years. With headquarters in Burlingame, California and a subsidiary in Peterborough, U.K., the company maintains a network of more than 40 distributors across the globe. A privately held company, Vector Laboratories was acquired by Maravai LifeSciences in 2016.

Contacts for the media:

Jennifer Dahlgren
Dahlgren Communications
530-263-6817
[email protected]

David Weber, Chief Commercial Officer
Maravai LifeSciences
(650) 464-4908
[email protected]